PMID- 12370744
OWN - NLM
STAT- MEDLINE
DCOM- 20030304
LR  - 20141120
IS  - 1019-6439 (Print)
IS  - 1019-6439 (Linking)
VI  - 21
IP  - 5
DP  - 2002 Nov
TI  - Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: 
      relationship with gene amplification, clinicopathological parameters and 
      prognostic outcome.
PG  - 981-7
AB  - Amplification of the c-erbB-2 oncogene and protein overexpression are well-known 
      in breast cancer and a basis for therapy with the monoclonal antibody 
      trastuzumab, which binds to the receptor encoded by c-erbB-2. Regarding bladder 
      carcinoma, several studies have examined c-erbB-2 expression, but their results 
      are quite heterogeneous. In the present study, we evaluated the expression of 
      this oncoprotein immunohistochemically in 203 muscle-invasive urothelial bladder 
      carcinomas using the HercepTest. Additionally, 42 cases were studied for gene 
      amplification by fluorescence in situ hybridization (FISH) using the PathVysion 
      kit. Follow-up was known in 147 patients. The results were compared with 
      pathologic characteristics and disease-related survival. Immunohistochemical 
      c-erbB-2 overexpression was observed in 37% of the tumors (76/203). However, only 
      5% (2/42) showed amplification of the oncogene, indicating that predominantly 
      other mechanisms than gene amplification may cause protein overexpression in 
      bladder cancer. C-erbB-2 protein overexpression was significantly associated with 
      high tumor grade (p=0.004) and infiltrative growth pattern (p=0.0001), and 
      tendentiously associated with the presence of lymph node metastases (p=0.077). 
      Regarding tumor stage, sex and age, no significant correlation was registered. 
      Kaplan-Meier curves showed a significantly worse disease-related survival for 
      patients with c-erbB-2 overexpressing tumors (p=0.0346 by log-rank test). 
      Multivariate analysis revealed that, besides nodal status (p=0.0001) and tumor 
      stage (p=0.028), c-erbB-2 overexpression was an independent predictor of 
      disease-related survival (p=0.030). Thus, our results suggest that 
      immunohistochemical c-erbB-2 detection might represent an additional tool in 
      determining bladder cancer prognosis. Clinical trials evaluating the efficacy of 
      trastuzumab therapy in bladder cancer patients are warranted.
FAU - Kruger, Stefan
AU  - Kruger S
AD  - Institut fur Pathologie, Universitatsklinikum Lubeck, Ratzeburger Allee 160, 
      D-23538 Lubeck, Germany. krueger@patho.mu-luebeck.de
FAU - Weitsch, Georg
AU  - Weitsch G
FAU - Buttner, Hartwig
AU  - Buttner H
FAU - Matthiensen, Arne
AU  - Matthiensen A
FAU - Bohmer, Torsten
AU  - Bohmer T
FAU - Marquardt, Tim
AU  - Marquardt T
FAU - Sayk, Friedhelm
AU  - Sayk F
FAU - Feller, Alfred C
AU  - Feller AC
FAU - Bohle, Andreas
AU  - Bohle A
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Int J Oncol
JT  - International journal of oncology
JID - 9306042
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - *Gene Amplification
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Muscles
MH  - Neoplasm Invasiveness
MH  - Prognosis
MH  - Receptor, ErbB-2/*analysis
MH  - Urinary Bladder Neoplasms/*chemistry/genetics/pathology
EDAT- 2002/10/09 04:00
MHDA- 2003/03/05 04:00
CRDT- 2002/10/09 04:00
PHST- 2002/10/09 04:00 [pubmed]
PHST- 2003/03/05 04:00 [medline]
PHST- 2002/10/09 04:00 [entrez]
PST - ppublish
SO  - Int J Oncol. 2002 Nov;21(5):981-7.